BioSpace News Archive

Persica Pharmaceuticals Ltd announces that Peter Hamlyn, founding member and Non-Executive Director of Persica will be presenting at the 2022 British Association of Spine Surgeons meeting, taking place in Belfast on 23-25 March 2022.

Affimed N.V., a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced that it will release full year 2021 results and corporate update on Thursday, March 31, 2022.

Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that the Company has dosed the first patient in ADVANCED-1, its Phase 1 clinical trial evaluating TARA-002, an investigational cell-based immunopotentiator, for the treatment of non-muscle invasive bladder cancer (NMIBC).

Pixium Vision SA announces that Lloyd Diamond, Chief Executive Officer of Pixium Vision, has been invited to present at the 2022 Virtual Growth Conference, presented by Maxim Group LLC and hosted by M-Vest from March 28 to 30, 9.00 am to 5.00 pm EDT / 3.00 pm to 11.00 pm CET.

INVO Bioscience, Inc. (NASDAQ: INVO), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and the IVC procedure it enables, will report financial results for its fourth quarter and fiscal year 2021, ended December 31, 2021.

TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today reported financial results for the fourth quarter and year-end December 31, 2021, and provided an update on recent corporate and clinical developments.

Today, Movano Inc. (NASDAQ:MOVE) reported financial results for the three months ending December 31, 2021 and provided a business update.

Edesa Biotech, Inc. announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules with a single healthcare-focused institutional investor of 2,739,727 of the Company’s common shares at a purchase price of $3.65 per common share.

Statera Biopharma, Inc. announced the closing of its previously announced underwritten public offering of 12,555,555 units, at a price to the public of $0.45 per Unit for aggregate gross proceeds of approximately $5.7 million, prior to deducting underwriting discounts, commissions, and other estimated offering expenses.

Landos Biopharma, Inc. (NASDAQ: LABP), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today announced financial results for the fourth quarter and full year ended December 31, 2021, and provided a business update.